Cohort Studymoderate evidence
Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the USA.
Climacteric : the journal of the International Menopause Society·December 1, 2025·PMID 40773298
Why it mattersMenopausal hormone therapy formulation may influence cardiovascular safety, yet real-world comparative data are limited. This study provides evidence that body-identical oral E2/P4 is associated with substantially fewer MACE events than CEE/MPA, informing risk-benefit discussions for hormone therapy selection in clinical practice.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled